Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.92)
# 204
Out of 4,512 analysts
486
Total ratings
62.9%
Success rate
25.4%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | n/a | $536.86 | - | 14 | Jul 14, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,370 | $1,152.54 | +18.87% | 36 | Jul 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $145 | $131.27 | +10.46% | 22 | Jul 7, 2026 | |
| INCY Incyte | Maintained: Hold | n/a | $114.88 | - | 36 | Jul 2, 2026 | |
| IVA Inventiva | Reiterated: Buy | n/a | $4.40 | - | 4 | Jul 2, 2026 | |
| ABSI Absci | Reiterated: Buy | $11 → $17 | $10.23 | +66.18% | 10 | Jul 2, 2026 | |
| SEPN Septerna | Reiterated: Buy | $43 | $34.54 | +24.49% | 6 | Jul 1, 2026 | |
| KYMR Kymera Therapeutics | Rated: Buy | $136 | $112.08 | +21.34% | 23 | Jun 29, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Buy | n/a | $39.73 | - | 34 | Jun 17, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $70 | $56.59 | +23.70% | 9 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $9.34 | - | 1 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.93 | - | 3 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $6.74 | +78.04% | 12 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.57 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $33.29 | - | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $106 | $81.93 | +29.38% | 37 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $56.95 | - | 21 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $8.27 | +20.92% | 15 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.14 | - | 7 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.65 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $53.78 | - | 29 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $355.25 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $110.11 | +94.35% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $22.98 | +0.09% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $656.12 | +23.76% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $106.18 | -20.89% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.45 | - | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $191.95 | -26.02% | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | n/a | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $120.78 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.25 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $244.78 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.31 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $62.78 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $5.57 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.00001 | n/a | 7 | Mar 20, 2023 |
Madrigal Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $536.86
Upside: -
Eli Lilly and Company
Jul 9, 2026
Reiterated: Buy
Price Target: $1,370
Current: $1,152.54
Upside: +18.87%
Protagonist Therapeutics
Jul 7, 2026
Reiterated: Buy
Price Target: $145
Current: $131.27
Upside: +10.46%
Incyte
Jul 2, 2026
Maintained: Hold
Price Target: n/a
Current: $114.88
Upside: -
Inventiva
Jul 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.40
Upside: -
Absci
Jul 2, 2026
Reiterated: Buy
Price Target: $11 → $17
Current: $10.23
Upside: +66.18%
Septerna
Jul 1, 2026
Reiterated: Buy
Price Target: $43
Current: $34.54
Upside: +24.49%
Kymera Therapeutics
Jun 29, 2026
Rated: Buy
Price Target: $136
Current: $112.08
Upside: +21.34%
Edgewise Therapeutics
Jun 17, 2026
Maintained: Buy
Price Target: n/a
Current: $39.73
Upside: -
MBX Biosciences
Jun 15, 2026
Reiterated: Buy
Price Target: $70
Current: $56.59
Upside: +23.70%
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.34
Upside: -
May 29, 2026
Maintained: Buy
Price Target: n/a
Current: $2.93
Upside: -
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $6.74
Upside: +78.04%
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $10.57
Upside: -
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $33.29
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $106
Current: $81.93
Upside: +29.38%
May 1, 2026
Maintained: Buy
Price Target: n/a
Current: $56.95
Upside: -
May 1, 2026
Maintained: Hold
Price Target: $10
Current: $8.27
Upside: +20.92%
Apr 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.14
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.65
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $53.78
Upside: -
Nov 5, 2025
Maintained: Hold
Price Target: n/a
Current: $355.25
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $110.11
Upside: +94.35%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $22.98
Upside: +0.09%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $656.12
Upside: +23.76%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $106.18
Upside: -20.89%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.45
Upside: -
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $191.95
Upside: -26.02%
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $120.78
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $24.25
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $244.78
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $1.31
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $62.78
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $5.57
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.00001
Upside: n/a